EcoDrugPlus

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSPNYG00000022746
Gene Symbol: PSMA6
3 Cross references
244 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSPNYG00000013038
Gene Symbol: PSMA8
3 Cross references
182 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSPNYG00000016702
Gene Symbol: PSMB1
3 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSPNYG00000002470
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSPNYG00000006129
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSPNYG00000006010
Gene Symbol: PSMB4
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSPNYG00000005721
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSPNYG00000011734
Gene Symbol: PSMB8
3 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSPNYG00000022066
Gene Symbol: PSMC1
3 Cross references
281 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSPNYG00000018466
Gene Symbol: PSMC2
3 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSPNYG00000016691
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSPNYG00000022242
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).